+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Intravenous (IV) Iron Drugs - Global Strategic Business Report

  • PDF Icon

    Report

  • 354 Pages
  • February 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 1382362

Global Intravenous (IV) Iron Drugs Market to Reach $4.8 Billion by 2030

The global market for Intravenous (IV) Iron Drugs estimated at US$3 Billion in the year 2022, is projected to reach a revised size of US$4.8 Billion by 2030, growing at a CAGR of 5.9% over the analysis period 2022-2030. Ferric Carboxymaltose, one of the segments analyzed in the report, is projected to record 6.3% CAGR and reach US$2.3 Billion by the end of the analysis period. Growth in the Iron Dextran segment is estimated at 5.1% CAGR for the next 8-year period.

The U.S. Market is Estimated at $1.1 Billion, While China is Forecast to Grow at 10.4% CAGR

The Intravenous (IV) Iron Drugs market in the U.S. is estimated at US$1.1 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$658.4 Million by the year 2030 trailing a CAGR of 10.4% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3% and 4.5% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Select Competitors (Total 33 Featured)

  • AbbVie Inc (AbbVie)
  • Akebia Therapeutics, Inc.
  • American Regent, Inc.
  • Covis Pharma GmbH.
  • Daiichi Sankyo Company, Ltd.
  • Galenica Group
  • Iron4u Aps
  • NIPPON SHINYAKU CO., LTD.
  • Pharmacosmos A/S
  • Rockwell Medical, Inc.
  • Sanofi S.A.
  • Shield Therapeutics Plc
  • Vifor Pharma Management Ltd.

Economic Outlook

The global economic outlook is improving, and growth recovery, albeit on the lower side, is expected for this year and the next. The United States although witnessing slowing GDP growth in response to tight monetary and financial conditions, has nevertheless overcome the recession threat. Easing of headline inflation in Euro area is helping boost real incomes and is contributing to pick-up in economic activity. China is expected to see strong increases in GDP in the coming year as the pandemic threat recedes and the government sheds its zero-COVID policy. With optimistic GDP projections, India remains on-course to emerge into a US trillion economy by 2030, surpassing Japan and Germany.

The upturn, however, remains fragile and a number of interlocking challenges continue to run in parallel, such as continued uncertainty around the war in Ukraine; slower than expected decline in global headline inflation; continuation of food and fuel inflation as a persistent economic problem for most developing countries; and still high retail inflation and its impact on consumer confidence and spending. Countries and their governments are showing signs of weathering these challenges, which helps lift market sentiments. As governments continue to combat inflation to get it down to more economically conformable levels by raising interest rates, new job creation will slowdown and impact economic activity. Stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced.

Although corporate investments can likely be held back by inflation worries and weaker demand, rise of new technologies will reverse partially this prevailing investment sentiment. Rise of generative AI; applied AI; industrializing machine learning; next-generation software development; Web3; cloud and edge computing; quantum technologies; electrification and renewables and climate technologies beyond electrification and renewables, will open up the global investment landscape. The technologies hold the potential to drive sizeable incremental growth and value to global GDP in the coming years. The short-term is expected to be a mixed bag of challenges and opportunities for both consumers and investors alike. There is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

What`s New?

  • Special discussions on the global economic climate and market sentiment
  • Coverage on global competitiveness and key competitor percentage market shares
  • Market presence analysis across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and trademarked research platform
  • Complimentary updates for one year
  • Access to curated YouTube video transcripts of market sentiments shared by CEOs, domain experts and market influencers via interviews, podcasts, press statements and event keynotes
Frequently Asked Questions about the Intravenous (IV) Iron Drugs Market

What is the estimated value of the Intravenous (IV) Iron Drugs Market?

The Intravenous (IV) Iron Drugs Market was estimated to be valued at $3 Billion in 2022.

What is the growth rate of the Intravenous (IV) Iron Drugs Market?

The growth rate of the Intravenous (IV) Iron Drugs Market is 6.1%, with an estimated value of $4.8 Billion by 2030.

What is the forecasted size of the Intravenous (IV) Iron Drugs Market?

The Intravenous (IV) Iron Drugs Market is estimated to be worth $4.8 Billion by 2030.

Who are the key companies in the Intravenous (IV) Iron Drugs Market?

Key companies in the Intravenous (IV) Iron Drugs Market include AbbVie Inc (AbbVie), Akebia Therapeutics, Inc., American Regent, Inc., Covis Pharma GmbH., Daiichi Sankyo Company, Ltd., Galenica Group, Iron4u Aps, NIPPON SHINYAKU CO., LTD., Pharmacosmos A/S and Rockwell Medical, Inc..

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Iron Deficiency Anemia (IDA) - A Major Global Health Concern
  • Iron Deficiency Prevalence by Disease: Analyzed by Percentage Number of Patients with ID and IDA in CKD (with dialysis), Non-Dialysis-CKD, Congestive Heart Failure, Chemotherapy Induced Anemia, Irritable Bowel Disease, Patient Blood Management (Surgery), Heavy Uterine Bleeding and Postpartum (OB-GYN)
  • Impact of Covid-19 and Global Economic Update
  • War & Inflation Supersede COVID-19 as Major Downside Risks for the Global Economy in 2023 & Beyond
  • Here’s How Inflationary Pressures Affect the Economy
  • Russia-Ukraine War, the Primary Culprit Responsible for the Hardships
  • Stubbornly High Inflation to Single Handedly Drag Down Global Growth
  • Here’s What’s Causing the Current Spike in Inflation
  • War-Induced Commodity Price Increases & Broad Based Price Pressures Mark the Return of Global Inflation in 2022 to the Highest Level Seen Since 1996: Global Inflation Rates (In %) for the Years 2019 Through 2024
  • War, Global Inflation, Cost of Living Crisis, Failed Fiscal Policy Attempts to Restore Price Stability & Contain Downside Risks to Result in Sharper-Than-Expected Slowdown in Global Economic Growth: World Economic Growth Projections (Real GDP, Annual % Change) for the Years 2020, 2021, 2022 and 2023
  • Recession Triggered by Uncontrolled Inflation or Unemployment, Which is the Greater Evil? Inflation Battling Policy Measures to Slowdown Post Pandemic Recovery in Unemployment Rates: Global Number of Unemployed People (In Million) for Years 2019 Through 2023
  • Competitive Landscape
  • Intravenous (IV) Iron Drugs - Global Key Competitors Percentage Market Share in 2023 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2023 (E)
  • Global Market Overview and Prospects
  • Global Intravenous Iron Drugs Market Driven by Rising Incidence of CKD and Cancer
  • Ferric CarboxyMaltose Dominates the Global Intravenous Iron Drugs Market
  • CKD Leads the Application Segment, Cancer Expected to Witness Fastest Growth
  • North America and Europe Hold Major Share, Asia-Pacific Witnesses Rapid Growth
  • Low- and Mid-income Countries Present Lucrative Penetration Opportunities for IV Iron Drugs
  • The Target Patient Populations
  • Leading Intravenous Iron Drugs Globally
  • Leading IV Iron Drugs Available in the Market
  • Leading Intravenous Iron Drugs: In a Nutshell
  • Ferinject/Injectafer - The Leading Intravenous Iron Drug Globally
  • Worldwide Ferinject (Injectafer) Sales (in US$ Million): 2018-2022E
  • Venofer®
  • Worldwide Venofer Sales (in US$ Million): 2018-2022E
  • Feraheme
  • Worldwide Feraheme Sales (in US$ Million): 2018-2022E
  • Gluconate (Ferrlecit® and Nulecit)
  • Dextran
  • Monoferric
  • Triferic AVNU
  • INFeD
  • Recent Market Activity
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Expanding Pool of ESRD and CKD Patients - The Major Growth Driver for Intravenous (Iv) Iron Drugs
  • ESRD Prevalence Worldwide: Number of Treated ESRD Patients Per Million Population in Select Countries for 2019
  • Global Population of Kidney Disease Patients Undergoing Treatment by Type of Modality (2019 and 2022P): Percentage Breakdown of Patients Undergoing Dialysis Therapy and Kidney Transplantation
  • Dialysis Patients - A Major Market for Intravenous Iron Supplements
  • Global Dialysis Patient Population Breakdown by Geographic Region/Country (2019 and 2024)
  • Global Dialysis Patient Population Distribution by Modality for Select Countries (2016): Percentage Breakdown of Hemodialysis (HD) and Peritoneal Dialysis (PD) Patients
  • Ageing Population Drives Demand for IV Iron Drugs
  • Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
  • Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
  • Rising Incidence of Cancer and the Associated Anemia Drives the Demand for Intravenous Iron Drugs
  • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
  • Breakdown of Total Number of Cancer Cases by Region: 2020
  • Breakdown of Total Number of Cancer Cases by Type: 2020
  • Rising Incidence of Diabetes to Propel the Market for Intravenous Iron Drugs
  • World Diabetes and Population Statistics (2019, 2030 & 2045)
  • Global Prevalence of Diabetes: Number of Adults Diagnosed with Diabetes (in Million) by Gender for 2019, 2030, and 2045
  • Increase in Healthcare Spending Bodes Well for Intravenous Iron Drugs Market
  • Healthcare Expenditure as a % of GDP by Region for 2019
  • Shifting Preference from Oral Iron Drugs to Intravenous Iron Drugs
  • Comparison of Ferrous Salts with IV Iron Therapy
  • 2020: Pharmacosmos Receives FDA Approval for Single Dose Infusion of Ferric Derisomaltose in IDA Patients
  • Other Chronic Diseases with IDA Offer Prospects for IV Iron Drugs
  • New Study Demonstrates IV Iron to Improve Long-term Outcomes in Heart Failure Patients
  • Incidence of Heart Failure (In 000s) in the U.S. by Gender for the Year 2022
  • Correction of IDA in Pregnancy Signals Opportunities
  • Women’s Health - A Key Growth Opportunity
  • Perioperative and Postoperative Anemia - A Niche Market Beckons
  • Adverse Reactions of IV Iron Preparations Raise Concerns
  • Dosing Limitations Plague IV Iron Market
  • Select Therapeutic Areas and the Required Iron Doses
4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Ferric Carboxymaltose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 2: World Historic Review for Ferric Carboxymaltose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 3: World 16-Year Perspective for Ferric Carboxymaltose by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Iron Dextran by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 5: World Historic Review for Iron Dextran by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 6: World 16-Year Perspective for Iron Dextran by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for Iron Sucrose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 8: World Historic Review for Iron Sucrose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 9: World 16-Year Perspective for Iron Sucrose by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 11: World Historic Review for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 12: World 16-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • TABLE 13: World Recent Past, Current & Future Analysis for Chronic Kidney Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 14: World Historic Review for Chronic Kidney Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 15: World 16-Year Perspective for Chronic Kidney Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 17: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 18: World 16-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • TABLE 19: World Recent Past, Current & Future Analysis for Inflammatory Bowel Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 20: World Historic Review for Inflammatory Bowel Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 21: World 16-Year Perspective for Inflammatory Bowel Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • TABLE 22: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 23: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 24: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • TABLE 25: World Intravenous (IV) Iron Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Intravenous (IV) Iron Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 28: World 16-Year Perspective for Intravenous (IV) Iron Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
III. MARKET ANALYSIS
  • UNITED STATES
  • Intravenous (IV) Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • CANADA
  • JAPAN
  • Intravenous (IV) Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • CHINA
  • Intravenous (IV) Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • EUROPE
  • Intravenous (IV) Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • FRANCE
  • Intravenous (IV) Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • GERMANY
  • Intravenous (IV) Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • ITALY
  • UNITED KINGDOM
  • Intravenous (IV) Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • SPAIN
  • RUSSIA
  • REST OF EUROPE
  • ASIA-PACIFIC
  • Intravenous (IV) Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • AUSTRALIA
  • Intravenous (IV) Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
  • INDIA
  • Intravenous (IV) Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
  • SOUTH KOREA
  • REST OF ASIA-PACIFIC
  • LATIN AMERICA
  • Intravenous (IV) Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
  • ARGENTINA
  • BRAZIL
  • MEXICO
  • REST OF LATIN AMERICA
  • MIDDLE EAST
  • Intravenous (IV) Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
  • IRAN
  • ISRAEL
  • SAUDI ARABIA
  • UNITED ARAB EMIRATES
  • REST OF MIDDLE EAST
  • AFRICA
  • Intravenous (IV) Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
IV. COMPETITION

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AbbVie Inc (AbbVie)
  • Akebia Therapeutics, Inc.
  • American Regent, Inc.
  • Covis Pharma GmbH.
  • Daiichi Sankyo Company, Ltd.
  • Galenica Group
  • Iron4u Aps
  • NIPPON SHINYAKU CO., LTD.
  • Pharmacosmos A/S
  • Rockwell Medical, Inc.
  • Sanofi S.A.
  • Shield Therapeutics Plc
  • Vifor Pharma Management Ltd.